Evidence map›Paper›PMID 34174071›Full record

GuidelineNeuro-oncology2021

SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors.

Tobias Walbert, Rebecca A Harrison, David Schiff, Edward K Avila, Merry Chen, Padmaja Kandula, Jong Woo Lee, Emilie Le Rhun, Glen H J Stevens, Michael A Vogelbaum and 4 more

Open access · bronzeAbstract readPractice GuidelineSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Neuro-oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 8 pooled it
30.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 8 syntheses or guidelines pooled it, 142 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Guideline
  9. Seizure prophylaxis in glioma surgery: a synopsis from the SPRING RCT.Health technology assessment (Winchester, England) · 2026
    Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Review
  16. Obstacles and Trials in Treating Primary Brain Tumors.International journal of molecular sciences · 2026
    Review
  17. Review
  18. Review
  19. Review
  20. Mapping integrated care for brain tumour-related epilepsy in the Italian RIN-IRCCS network.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 12 institutions in 3 countries.

Tobias WalbertDepartment of Neurology and Neurosurgery, Henry Ford Health System and Wayne State University, Detroit, Michigan, USA.
Rebecca A HarrisonDepartment of Neuro-oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
David SchiffDepartment of Neurology, University of Virginia Health System, Charlottesville, Virginia, USA.
Edward K AvilaDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Merry ChenDepartment of Neuro-oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Padmaja KandulaDivision of Clinical Neurophysiology and Epilepsy, New York Presbyterian Hospital-Weill Cornell Medicine, New York, New York, USA.
Jong Woo LeeDepartment of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID 0000-0001-5283-7476
Emilie Le RhunDepartment of Neurology and Neurosurgery, Brain Tumor Center & Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
Glen H J StevensRose Ella Burkhardt Brain Tumor and Neuro-oncology Center, Cleveland Clinic, Cleveland, Ohio, USA.
Michael A VogelbaumDepartment of NeuroOncology, Moffitt Cancer Center, Tampa, Florida, USA.
Wolfgang WickNeurology Clinic and Neurooncology Program, Heidelberg University and German Cancer Research Center, Heidelberg, Germany.
Michael WellerDepartment of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.ORCID 0000-0002-1748-174X
Patrick Y WenCenter For Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Elizabeth R GerstnerPappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
The University of Texas MD Anderson Cancer Center · USUniversity of Zurich · CHBrigham and Women's Hospital · USCenter for Neuro-Oncology · USCleveland Clinic · USGerman Cancer Research Center · DEHarvard University · USHenry Ford Health System · USMemorial Sloan Kettering Cancer Center · USMoffitt Cancer Center · USNewYork–Presbyterian Hospital · USUniversity of Virginia Health System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo update the 2000 American Academy of Neurology (AAN) practice parameter on anticonvulsant prophylaxis in patients with newly diagnosed brain tumors.

methodsFollowing the 2017 AAN methodologies, a systematic literature review utilizing PubMed, EMBASE Library, Cochrane, and Web of Science databases was performed. The studies were rated based on the AAN therapeutic or causation classification of evidence (class I-IV).

resultsThirty-seven articles were selected for final analysis. There were limited high-level, class I studies and mostly class II and III studies. The AAN affirmed the value of these guidelines. RECOMMENDATIONS: In patients with newly diagnosed brain tumors who have not had a seizure, clinicians should not prescribe antiepileptic drugs (AEDs) to reduce the risk of seizures (level A). In brain tumor patients undergoing surgery, there is insufficient evidence to recommend prescribing AEDs to reduce the risk of seizures in the peri- or postoperative period (level C). There is insufficient evidence to support prescribing valproic acid or levetiracetam with the intent to prolong progression-free or overall survival (level C). Physicians may consider the use of levetiracetam over older AEDs to reduce side effects (level C). There is insufficient evidence to support using tumor location, histology, grade, molecular/imaging features when deciding whether or not to prescribe prophylactic AEDs (level U).

Indexed as

AnticonvulsantsBrain NeoplasmsHumansPostoperative PeriodSeizuresValproic AcidAnticonvulsantsValproic Acidantiepileptic drugGBMgliomaguidelineseizure

Identifiers

PMID34174071
PMCPMC8563323
OpenAlexW3174034807

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.